|52 Week High||372.25|
|52 Week Low||231.87|
|Mkt. Cap ($ Billion)||352.62|
*Delayed by 20 seconds.
|Name||Price ($)||Change%||M.Cap(Billion $)||TTM PE||TTM EPS||DY||52 wk high/low||Technical Rating|
|Eli Lilly||371.08||1.96||352.62||43.71||8.49||1.21||372.25/231.87||4.15||Very Bullish|
|Merck & Co||110.12||1.18||279.40||14.39||7.66||3.20||110.29/71.50||10.49||Very Bullish|
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.